Mersana CEO details path forward after breakup with Takeda

Mersana executives discussed data from its ovarian and lung cancer drug trial Wednesday. The biotech also plans to disclose its next clinical candidate in the second half of 2019.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.